Dechert LLP > Boston, > Firm Profile

Dechert LLP
ONE INTERNATIONAL PLACE
40TH FLOOR, 100 OLIVER STREET
BOSTON, MA 02110-2605
MASSACHUSETTS

United States > Media, technology and telecoms > Cyber law (including data privacy and data protection) Tier 2

The experienced Brenda Sharton, co-chair of Dechert LLP‘s global privacy and cybersecurity practice from the Boston office, handles high profile data breaches, not limited to ransomware attacks and business email interruptions brought about by a range of threat actors, including nation states, organized crime groups and insiders. Sharton also defends clients against government investigations and enforcement actions brought by global and US regulators, namely the FTC, SEC and OCR for HIPAA breaches. Also working from Boston, trial litigator Timothy Blank advises technology, biotechnology and investment firms on privacy risks in relation to US state and global regulations, drafting security programs, class action defenses, responding to data breaches and FTC investigations. Los Angeles-based Kevin Cahill advises on complex and nuanced issues related to the scope of the CCPA’s GLBA carve-out and its impact on personal information collected from investors across various channels. Charlotte-stationed associate Hilary Bonaccorsi is a key contact for financial institutions and registered investment advisors on the SEC’s privacy regulations. Bonaccorsi also focuses on developing compliance programs related to the development and purchase of alternative data sets and web scrapping risks. Former co-chair Karen Neuman has retired.

Practice head(s):

Brenda Sharton

Testimonials

‘Brenda Sharton is a brilliant lawyer and a great client advocate. She is the lawyer you want in your corner. As a seasoned litigator and an experienced data security lawyer, she manages crises with confidence, finesse and strategy. Brenda will get into the weeds with the technical team and in the same breath turn to the legal team to interpret the significance and how it aligns with the bigger picture.’

‘Brenda Sharton is knowledgeable, sharp, insightful and responsive. She is very good at negotiating. She knows when to push hard and when to play soft tunes to foster good relationships with different government agencies.’

‘Dechert team is the top-tier attorney team on privacy policy and cyber security with a lot of experiences and knowledge. They solve the problems. They are super good at communication and always get to the key point. While they are knowledgeable with a lot of experiences, they are also receptive to different opinions.’ 

‘The team have a broad spectrum of knowledge and work very closely with clients. They provide expert advice along with pragmatic solutions.’ 

‘Dechert has assembled a truly global team of privacy and data security lawyers. The cross-practice specialization ensures that clients have access to lawyers dedicated to solving a range of client’s legal issues both proactively and reactively during a data security related crisis or a litigation.’

‘The practice is led by Brenda Sharton. She brings a wealth of experience to the firm.’ 

The privacy and security team collaborates seamlessly across the globe when advising clients.’

‘The outstanding lawyers I deal with are Hilary Bonaccorsi, Madeleine White, Olaf Fasshauer and Tim Blank. They all have an incredible work ethic and are able to distill the legal issues in a very simple and business-friendly way. They understand that legal solutions must work not just for the lawyers but for the businesses.’ 

Key clients

Flo Health, Inc.

Moderna, Inc.

Pearson, plc

Cano Health, Inc.

GIC Special Investments Pte. Ltd.

Easy Healthcare Corp

Rockstar Games

Chase Bank USA, N.A.

Work highlights

  • Advised Flo Health, on its regulatory and litigation matters around the globe—including a dozen class actions alleging privacy policy violations, and for advice on a new product feature designed to further protect user privacy in the face of the overturning of Roe v. Wade.
  • Advised Moderna as lead counsel, on privacy and cybersecurity matters related to safeguarding the vaccine and compliance with global privacy laws, as well as in connection with the publicized European Medicines Agency (EMA) data breach of Covid-19 vaccine information.
  • Advising Pearson on a cyberattack and the subsequent SEC investigation as well as other aspects related to privacy and cybersecurity counseling matters more generally.

United States > Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco) Tier 3

Primarily based in New York and California, Dechert LLP‘s product liability and mass torts team has a strong reputation, in particular, in the defense of consumer product-related healthcare and pharma matters. As well as handling many high-profile consolidated disputes relating to personal injury as a result of side effects following the use of drugs manufactured from brand-name pharma companies, the team also handles a growing number of healthtech-related disputes. In this regard, Los Angeles-based Benjamin Sadun is representing a well-known women’s health app in its global defense of alleged privacy violations. Outside of the healthcare and pharma space, the firm continues to defend 3M in the largest ever MDL to date brought by  US military veterans and service members alleging that their hearing loss was caused by defective earplugs sold to the US military. Los Angeles-based partner Sheila Birnbaum co-heads the overarching product liability and mass torts group alongside Mark S. Cheffo  in New York. Former co-head Kimberly Branscome moved to Paul, Weiss, Rifkind, Wharton & Garrison LLP in February 2024.

Practice head(s):

Sheila Birnbaum; Mark Cheffo

Other key lawyers:

Hayden Coleman; Bert Wolff; Jay Bhimani; Mara Cusker Gonzalez; Rachel Passaretti-Wu; Benjamin Sadun; Jonathan Tam

Key clients

3M Company

Easy Healthcare Corporation

Flo Health, Inc.

GlaxoSmithKline

GSK Consumer Healthcare Holdings

Viatris (Formerly Pfizer)

Work highlights

  • Representing 3M in product liability litigation involving allegations that a product sold to the military is related to hearing loss suffered by servicemen and women.
  • Representing Easy Health Corporation and its women’s mobile health fertility App (Premom) in connection with a pending purported class action.
  • Representing Viatris in defending claims by thousands of plaintiffs alleging that Lipitor caused them to develop type 2 diabetes.

United States > Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings) Tier 4

Dechert LLP‘s Boston-based practice is co-led by Andrea Reid and Andrew Wilkins, who is described as ‘one of the best IP counsel’. The team is adept at advising on prosecution in a multitude of areas, though there is an evident expertise across the board in biotech, with the team being noted as a ‘terrific partner when it comes to new technologies’. Additionally, its work in life sciences and pharmaceuticals is noteworthy, a key example being Reid and the ‘business-centric’ and ‘excellent’ Chad Davis representing AVEO Oncology on the $566m multi-jurisdictional creation of its patent portfolio following its acquisition by LG Chem. Scott Warren  left the firm in August 2022.

Practice head(s):

Andrea Reid; Andrew Wilkins

Other key lawyers:

Testimonials

‘The Dechert team is great at devising IP strategy to meet corporate needs. They offer aggressive solutions to maintain the best possible IP position, ensuring it meets deadlines and timelines. They are a terrific partner when it comes to new technologies and being able to adopt a strategy that is defensive against competition.’

‘Chad Davis is incredibly organized and is always on top of our needs and patent update timelines. He has a great attitude and is always responsive.’

‘They have an extremely deep knowledge of the biologics space and are very responsive to client requests.’

‘Andrew Wilkins is one of the best IP counsel I’ve worked with. He’s able to quickly work through the most complex issues and come up with practical guidance.’

‘Chad Davis and his team provide excellent, timely, thoughtful and effective service. They provide forward-looking cost estimates that help budget forecasting.’

‘Chad Davis has a business-centric approach to IP, incorporating business strategy in his recommendations on patent prosecutions.’

‘The team we work with has an in-depth knowledge of the IP landscape but also understands what is required from an IP strategy perspective within a small biotech company. They are very responsive and provide clear guidance on current IP prosecution needs. We do a lot of work with academics and they do a great job of ensuring we get the most from those interactions, both from a legal contract and an IP licence perspective.’

‘Andrew Wilkins is very responsive and pragmatic in his approach, which ensures that issues are dealt with quickly and efficiently.’

Key clients

Agenus

argenx

Atlas Venture

AVEO Oncology

Bicycle Therapeutics

Brickell Biotech

Exo Therapeutics

Forbion Capital Partners

Homology Medicines

Ikena Oncology

Kymera Therapeutics

Matchpoint Therapeutics

Nimbus Therapeutics

Parthenon Therapeutics

PIC Therapeutics

Rectify Pharmaceuticals

ROME Therapeutics

Tectonic Therapeutics

Third Harmonic Bio

Vigil Neuroscience

Work highlights

  • Representing Boston-based oncology-focused biopharmaceutical company AVEO Oncology in its $566m definitive agreement with LG Chem to acquire AVEO for $15 per share.
  • Advised Third Harmonic Bio on patent strategy and IP diligence relating to its $185m IPO.
  • Represented Homology Medicines in the establishment of its $180m joint venture with Oxford Biosciences, a UK-based gene therapy firm and contract development and manufacturing organization.

United States > Investment fund formation and management > Mutual/registered/exchange-traded funds

The blue chip client base of Dechert LLP‘s investment funds department appreciate its ‘great depth in its mutual fund practice‘. The firm is a strong choice for the gamut of issues in the space, covering formation and fund raising, day-to-day operations, regulatory compliance, and all potential disputes. The sizeable practice includes many practitioners with experience as in-house counsel and regulators, and clients include funds, advisers, boards of directors and audit committees, independent directors, broker-dealers, insurance companies, and banks. Recent work has included a number of conversions from mutual funds to exchange-traded funds, following the national trend, and the regulatory side of the practice has been busy with new SEC regulations. Christopher Harvey oversees the practice from the firm’s Boston office and is a leading figure in the market. Alongside him, Christopher Christian is a key contact for US and European asset managers and investment funds, and John O’Hanlon is a regulatory expert. In New York, Allison Fumai stands out for her ETF expertise, while Washington DC is another key location, where Megan Johnson and Douglas Dick are based. San Francisco-based Mark Perlow is recommended by clients as ‘one of the most respected mutual fund/investment adviser attorneys‘.

Practice head(s):

Christopher Harvey

Other key lawyers:

Christopher Christian; Allison Fumai; Mark Perlow; John O’Hanlon; Douglas Dick; Stephen Bier; Thomas Bogle; Megan Johnson; Adam Teufel; Stephanie Capistron

Testimonials

‘Dechert has great depth in its mutual fund practice, and the ability to address emerging best practices and evolving standards. In addition, it has broad capabilities and is able to support a variety of issues that arise tangentially to the core mutual funds practice and is our first “go to” for many of these other issues.’

‘Mark Perlow has a deep background in the mutual fund and investment adviser space, and his former SEC experience provides context for not only the details of regulations but also the policy and practical implications of a variety of matters. He is one of the most respected mutual fund/investment adviser attorneys providing confidence that we will address new requirements correctly.’

Key clients

MainStay Funds

Morgan Stanley Funds

abrdn plc

Work highlights

  • Advised MainStay Funds on all its US mutual funds and closed-end funds, as well as the funds’ board and its independent trustees.
  • Advised Morgan Stanley Funds on its US mutual funds, exchange-traded funds, closed-end funds, BDC and CLOs.
  • Advised Abrdn on its US registered closed-end funds, mutual funds, and ETFs.

United States > Healthcare > Life sciences

Regarded by some clients as ‘easily the best', Dechert LLP’s global life sciences practice often handles patent and IP litigations, contentious antitrust matters, and product liability related issues. Working with a host of start-ups and mature pharmaceutical and biotech companies, Andrea Reid co-heads the team from Boston, drawing on her expertise in IP strategy and prosecution. Based in New York, the ‘truly exceptional‘ fellow co-chair David S Rosenthal maintains a corporate finance and life sciences M&A focused practice. Rosenthal routinely advises public and private investment banks and venture capital firms on IPOs and CMPOs looking to invest in life sciences and medical device companies. Also based in New York, Katherine Helm notably acts for biotech and pharmaceutical companies in biologics patent disputes before the PTAB.

Practice head(s):

Andrea Reid; David S. Rosenthal

Other key lawyers:

Melanie Thill-Tayara; Katherine Helm

Testimonials

‘The quality, competence, and knowledge of the firm is without peer, Dechert is easily the best. They pay attention to detail and are rigorous in all of their reviews.’

‘The team has a rapid grasp of technical issues and is incredibly supportive. I would strongly recommend them to anyone seeking their legal assistance in any matters relating to healthcare.’

‘David Rosenthal truly stands out in his field. He carefully researches matters of relevance, and is empathetic. He is a truly exceptional person.’

Key clients

Aquestive Therapeutics

BioAtla

BioDelivery Sciences

Biogen

Cerus Endovascular

Chiesi Pharmaceutical

CVS / Aetna

Eli Lilly and Company

Endo Pharmaceuticals

Flo Health

GlaxoSmithKline

Homology Medicines

Johnson & Johnson

Moderna Therapeutics

Nimbus Therapeutics

Pfizer / Viatris

Purdue Pharma

Third Harmonic Bio

Quest Diagnostics

Work highlights

  • Represented Eli Lilly & Co. in cases relating to their worldwide discovery authorized under 28 U.S.C § 1782, in a global patent litigation involving Novartis.
  • Advising Cerus Endovascular on its (up to) US$525 million purchase agreement to be acquired by Stryker Corporation.
  • Advised AVEO Oncology on its US$566 million definitive agreement with LG Chem to acquire AVEO for $15.00 per share, providing patent strategy and IP diligence.

United States > Tax > US taxes: non-contentious

Regarded for its involvement in the funds space, Dechert LLP underscores its reputation with instructions for leading global asset management firms and investment funds, as well as small and mid-sized complexes. Global tax chair Joshua Milgrim heads the practice, known for advising private equity firms and their portfolio companies on a broad range of corporate transactions, with a focus on the life sciences sector. Also sought out as lead counsel on various transactions are Elizabeth Guidi and David Passey. Philadelphia-based federal tax specialist Edward Lemanowicz handles international restructurings, while in Boston, Adrienne Baker focuses on partnership taxation, as well as private and regulated investment companies, including hedge funds and private equity funds. Among other key members are investment fund experts Joseph Riley and Ari Zak, whose combined expertise encompasses digital currencies and insurance. All named individuals are based in New York unless stated otherwise.

Practice head(s):

Joshua Milgrim

Key clients

GIC

T. Rowe Price

JP Morgan Chase & Co.

GQG Partners

Court Square Capital Partners

Griffon Corp.

SciPlay

Stifel Financial Corp.

One Equity Partners

StepStone

Work highlights

  • Advised GIC as part of an investor group including Blackstone, Carlyle and Hellman & Friedman, on the $34bn acquisition of a majority stake in Medline.
  • Advising T. Rowe Price Group on its definitive agreement to purchase Oak Hill Advisors, acquiring 100% of the equity of OHA and other entities that have common ownership for a purchase price of up to $4.2bn.
  • Advised Griffon Corporation on its $845m acquisition, through its subsidiary The AMES Companies, Inc., of the Hunter Fan Company from MidOcean Partners.

United States > Finance > Capital markets: debt offerings

Dechert LLP continues to be rated for its expertise in life sciences and permanent capital vehicles; it is a dominant force in issuances by business development companies (BDCs). It recently advised Blackstone Private Credit Fund on its $500m private placement of 2.700% senior secured notes due 2025 and $650m private placement of 4.000% senior secured notes due 2029. Jay Alicandri is a major force in DCM offerings in the permanent capital and private credit segments. Boston partner Thomas Friedmann is co-head of corporate finance and capital markets and co-head of permanent capital, frequently advising on capital markets offerings by BDCs.

Practice head(s):

Thomas Friedmann; David Rosenthal

Other key lawyers:

Ian Hartman; Matthew Carter; Eric Siegel; Harry Pangas; Jay Alicandri

Key clients

Aquestive Therapeutics

B&G Foods

Bain Capital Specialty Finance

BC Partners

BioAtla

Blackstone

Business Development Company of America

Diffusion Therapeutics

EaglePoint Credit Company

FS Investment Corporation

Golub Capital BDC, Inc.

Griffon Corporation

Hercules Capital

Horizon Technology Finance

Main Street Capital Corporation

PennantPark Investment Corporation/PennantPark Floating Rate Capital

Piper Sandler

Raymond James

Stifel

TriplePoint Capital

Via Optronics

WhiteHorse Finance

Work highlights

  • Advised Blackstone Private Credit Fund on its $500m private placement of 2.700% senior secured notes due 2025 and $650m placement of 4.000% senior secured notes due 2029.
  • Advised Cliffwater Corporate Lending Fund in connection with its $1.82bn revolving and term loan facilities, and $900m 4.10% Series A Senior Secured Notes due March 2027.
  • Advised Cliffwater Corporate Lending Fund in connection with its $635m offering of senior secured notes comprised of multiple tranches.

United States > Finance > Capital markets: equity offerings

Dechert LLP’s capital markets practice remains closely associated with life sciences and permanent capital vehicles, including business development companies. It is also noted for cross-border offerings, including those from Latin America. Thomas Friedmann, Boston managing partner and co-chair of the capital markets group, is noted for permanent capital vehicle transactions. New York partner David S Rosenthal co-heads the capital markets group and has a long track record in life sciences transactions.

Practice head(s):

Thomas Friedmann; David Rosenthal

Key clients

Aquestive Therapeutics

B&G Foods

Bain Capital Specialty Finance

BC Partners

BioAtla

Blackstone

Business Development Company of America

Diffusion Therapeutics

EaglePoint Credit Company

FS Investment Corporation

Golub Capital BDC, Inc.

Griffon Corporation

Hercules Capital

Horizon Technology Finance

Main Street Capital Corporation

PennantPark Investment Corporation/PennantPark Floating Rate Capital

Piper Sandler

Raymond James

Stifel

TriplePoint Capital

Via Optronics

WhiteHorse Finance

Work highlights

  • Advised Cerus Endovascular on its negotiated sale to Stryker Corporation by way of a scheme of arrangement under Part 26 of the United Kingdom Companies Act 2006 (as amended).
  • Represented Golub Capital BDC 4 in the organisation and launch of a business development company, including private placement of shares of common stock.
  • Advised the special committee of the board of directors of SLR Senior Investment Corp in connection with its merger with SLR Investment Corp.

United States > Finance > Capital markets: global offerings

Dechert LLP has an established record in cross-border offerings, particularly those involving Latin America. It is also active in cross-border offerings for permanent capital vehicles and business development companies. Recently, it advised Blackstone Private Credit Fund, a closed-end management investment company and business development company, on its inaugural euro-dominated offering of €500m of 1.750% Notes due 2026. Boston’s Thomas Friedmann and New York partner David S Rosenthal, a life sciences specialist, co-chair the capital markets practice. Howard Kleinman departed for McDermott Will & Emery LLP in July 2023.

Practice head(s):

Thomas Friedmann; David Rosenthal

Work highlights

United States > Finance > Capital markets: high-yield debt offerings

Also noted for its capabilities in life sciences-related work, Dechert LLP‘s strength in offerings by financial institutions, including permanent capital vehicles, provides a platform for a steady pipeline of debt offering engagements. New York partner Jay Alicandri is active in high-yield debt offerings in the permanent capital and private credit sphere. Boston’s Thomas Friedmann and Philadelphia partner Ian Hartman are also key partners within the national practice.

Practice head(s):

Thomas Friedmann; David Rosenthal

Other key lawyers:

Dechert is a global law firm that advises asset managers, financial institutions and corporations on issues critical to managing their business and their capital – from high-stakes litigation to complex transactions and regulatory matters. We answer questions that seem unsolvable, develop deal structures that are new to the market and protect clients’ rights in extreme situations. Our 1,000+ lawyers across 21 offices globally focus on the financial services, private equity, private credit, real estate, life sciences and technology sectors.

Dechert’s lawyers work together to understand their clients’ most complex legal and business problems and efficiently deliver practical and innovative solutions all over the world.

Our clients face increasingly challenging times, from geopolitical uncertainty and the increasing scope of compliance requirements, to a proliferation of commercial and regulatory risks. We partner with businesses to navigate these situations, supporting clients in achieving their commercial goals. Our method is agile and intuitive.

We have some of the world’s leading lawyers advising on both domestic and cross-border matters. The firm is frequently retained to work on the most challenging transactions and disputes, and prides itself on its ability to deliver premium legal services and sound business judgment to its clients. We create strategies that protect both commercial and private interests with discretion and sensitivity.

Dechert lawyers bring to all of their assignments a focus on quality, responsiveness and value for money. We are driven by one key principle: exceptional client service.

Technology and innovation are central to the future development of our business, both in terms of client-facing products and internal resources that enable more cost-effective operations, such as innovations in project management, eDiscovery and client-specific extranets.

Dechert has a longstanding tradition of providing pro bono legal services to individuals and organizations who cannot otherwise afford legal counsel. Lawyers in all our offices and in all our practice groups make a difference every day by contributing their talents to providing pro bono legal services. We approach pro bono efforts with the same energy, enthusiasm and resources as work for commercial clients, and associates receive billable hour credit for their pro bono work. We require all lawyers to perform at least 25 hours of pro bono work per year to ensure universal participation in our pro bono program.

Department Name Email Telephone
Financial services and Investment management Christopher Harvey
Corporate and securities Mark Thierfelder
Litigation Catherine Botticelli
Litigation Jonathan Streeter
Intellectual property Martin Black
Intellectual property Jeffrey Plies
Financial restructuring Allan Brilliant
Global finance Laura Swihart
Global finance Jay Alicandri
White collar defense and investigations David Kelley
Securities litigation David Kistenbroker
Securities litigation Joni Jacobsen
Antitrust Steven Bizar
Antitrust Mike Cowie
Employee benefits/executive compensation Steven Rabitz
Employee benefits/executive compensation Howard M. Klein
Tax Joshua Milgrim
International arbitration Arif Ali
Product Liability and Mass Torts Sheila Birnbaum
Product Liability and Mass Torts Kimberly Branscome

Dechert is a leading global law firm with 22 offices around the world. We advise on matters and transactions of the greatest complexity, bringing energy, creativity and efficient management of legal issues to deliver commercial and practical advice for clients.

History of the firm: Founded in Philadelphia in 1875, Dechert has advised on matters involving Latin America for more than three decades. Its international network of trusted local counsel is bolstered by the firm’s foreign lawyer program, where lawyers from Latin American relationship firms are seconded to Dechert and vice versa.

Main areas of practice
Corporate and securities: Dechert’s corporate lawyers have advised companies seeking to expand their traction both within and outside Latin America for more than three decades. The firm represents buyers, sellers and advisers in connection with mergers and acquisitions and joint ventures. Dechert also handles a full range of corporate finance transactions, including initial public offerings and follow-on equity offerings, Rule 144A and Regulation S offerings, rights offerings, tender and exchange offers, and sovereign debt offerings.

Financial restructuring: Dechert represents distressed companies, buyers of distressed assets, investors in debt, equity holders and creditors in every phase of the insolvency and corporate recovery lifecycle in Latin America. The firm focuses on achieving clients’ financial and business goals in the most expedient manner possible, including advocating on their behalf.

Financial services and asset management: Dechert offers a broad range of transactional and regulatory services to Latin American banks, broker-dealers, investment managers, insurance companies and other financial institutions. It works closely with local counsel to facilitate public and private offerings of foreign collective investment schemes across the region. The firm has assisted clients in listing exchange-traded funds on Latin American stock exchanges and facilitated the approval of shares/units of investment funds for sale to pension funds administrators in Chile and Peru.

Global investigations: Dechert has considerable experience investigating and advising on anti-corruption compliance issues in Latin America, as well as matters involving tax and accounting fraud, money laundering and insider trading. The firm brings particular expertise to bear on matters involving FCPA and UK Bribery Act compliance, and also advises on civil and cartel investigations.

International arbitration and litigation: Dechert lawyers have acted as counsel or arbitrator in landmark arbitration proceedings involving Latin American parties, acting for and against state parties, majority and minority shareholders in joint ventures, and independent contractors. The firm also advises clients regarding their rights and remedies under investment treaties and other international instruments.

Governments, global corporations, corporate and sovereign debt holders, hedge funds and other financial institutions rely on the firm’s international litigators to resolve their most intractable cross-border commercial disputes, whether before courts, administrative tribunals or regulatory bodies. Its recent experience includes handling cross-border insolvency, sovereign debt and other commercial disputes involving such countries as Argentina, Mexico, Panama, Peru and Nicaragua.

International trade: Dechert handles a wide range of international trade matters, including export controls, economic sanctions, trade embargoes, customs procedures, trade defense measures and national security reviews of foreign direct investment. The firm’s practitioners include former national and multinational officials, comprising regulators, compliance officers, enforcement agents, trade negotiators and public affairs experts.

Department Name Email Telephone
Chairman Andrew Levander
CEO Henry Nassau
Corporate and securities Mark Thierfelder mark.thierfelder@dechert.com
Financial restructuring Allan Brilliant allan.brilliant@dechert.com
Financial services and asset management Douglas Dick douglas.dick@dechert.com
Global investigations Hector Gonzalez hector.gonzalez@dechert.com
International arbitration Eduardo Silva Romero eduardo.silvaromero@dechert.com
International arbitration Arif Ali arif.ali@dechert.com
International trade Amanda DeBusk amanda.debusk@dechert.com
International trade Jeremy Zucker jeremy.zucker@dechert.com

COMPANY/FIRM: Citigroup
TESTIMONIAL: “Dechert consistently provides differentiating legal advice, particularly on large, complex transactions.”


COMPANY/FIRM: Sun Capital
TESTIMONIAL: “The firm did a great job throughout the entire process. They have been proactive and delivered quality advice. As always, a pleasure working with such a great team.”


COMPANY/FIRM: Credit Suisse
TESTIMONIAL: “We continually have the highest degree of confidence in the work product and coverage of the Dechert team, and they are always a pleasure to work with.”


COMPANY/FIRM: Saint-Gobain
TESTIMONIAL: “Saint-Gobain frequently turns to Dechert to defend the company in its most consequential, high-stakes litigation in the United States. Their sophistication, depth of experience, and legal creativity – especially in the area of complex mass tort litigation, is simply unrivalled. When the case is unprecedented and alleged to be perilous, there is no better partner to have in the trenches than Dechert.”


Leading from the Front

“Actionable allyship moves beyond passive solidarity and requires speaking up or intervening during acts of marginalization, even at the risk of backlash or negative consequences. As catalysts for change, Dechert remains committed to doing our part in fighting systemic racism, social injustice and inequity.”
Satra Sampson-Arokium, Chief Diversity, Equity and Inclusion Officer

  • Using his voice to take a powerful stand, our Chief Executive Officer, Henry Nassau, published a Leaders at the Front Pledge. His pledge is a bold action plan to create meaningful and measurable changes at Dechert and within the legal industry. Read his pledge here on the Leadership Council on Legal Diversity’s website.
  • In 2021, Dechert became one of the first firms to pilot the Mansfield Rule in the UK. The Mansfield Rule, overseen by Diversity Lab, has become the standard by which U.S. law firms track and measure their diversity.
  • Dechert was the first law firm to sign the Business Statement Opposing Anti-LGBTQ State Legislation, taking a stance against discrimination of LGBTQ people in proposed U.S. legislation.

By the Numbers

  • 43% of the Policy Committee [senior leadership team] are women or diverse partners.
  • 52% of the lawyers most recently promoted to partner [effective January 1, 2022] are women.
  • 44% of our global offices are managed by women or diverse partners.
  • 25% of partners globally are women.
  • 74% of our most recent Fall 2021 class of new associates in the U.S. are women or diverse.

Key Initiatives

Aspiring Solicitors
Dechert is an Affiliate Partner of Aspiring Solicitors (AS). 2021 marks the fifth successful year of Dechert’s sponsorship of the organization’s national Commercial Awareness Competition, with the winners offered a vacation scheme and opportunity to interview for a training contract at Dechert.

Diversity and Inclusion Week
During the firm’s second annual DEI Week, Dechert hosted a conversation with Dr. Makaziwe Mandela, the eldest daughter of President Mandela, who shared insights on her family’s work to bring greater unity to the world. Our community also joined in to connect across differences and inspired each other to take a break by sharing their favorite vacation or staycation photo, making a difference with acts of kindness, and some other lighthearted and fun moments

Sponsorship and Sustained Support (SASS) Program
Through our Global Women’s Initiative, we continued to identify and implement initiatives that promote opportunities for women to advance and lead throughout the firm. We continued to organize our SASS women into several cohorts led by partner faculty. SASS cohorts are designed to provide support and actionable skills as women continue learning and networking together to navigate the path to partnership.

Inclusive Leadership
Commitment to diversity and inclusion stems from the top. Our partners have been participating in interactive sessions on inclusive leadership since 2018. In 2021, the training expanded to the entire Dechert community. We covered such issues as affinity bias, attribution bias, covering, in and out groups, actionable allyship, unconscious bias, and inclusive leadership in times of crisis. Individuals participate in interactive sessions that center around dramatizations that prompt conversations, challenge stereotypes, and inspire change.